The Parkinson Study Group
18
2
2
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
5.6%
1 terminated/withdrawn out of 18 trials
90.9%
+4.4% vs industry average
17%
3 trials in Phase 3/4
60%
6 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Study in Parkinson Disease of Exercise
Role: collaborator
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
Role: collaborator
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
Role: collaborator
Parkinson's Foundation PD GENEration Genetic Registry
Role: collaborator
PDGeneration: Mapping the Future of Parkinson's Disease
Role: collaborator
Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials
Role: collaborator
Auricular Muscle Zone Stimulation for Parkinson Disease
Role: collaborator
Study of Urate Elevation in Parkinson's Disease, Phase 3
Role: collaborator
Validation of a Non-Motor Fluctuation Assessment Instrument (NoMoFA) for Parkinson's Disease
Role: collaborator
Efficacy of Isradipine in Early Parkinson Disease
Role: collaborator
Safety of Urate Elevation in Parkinson's Disease
Role: lead
Nicotine Treatment of Impulsivity in Parkinson's Disease
Role: collaborator
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Role: collaborator
Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
Role: collaborator
Parkinson's Research: The Organized Genetics Initiative
Role: collaborator
Diagnostic and Prognostic Biomarkers in Parkinson Disease
Role: lead
A Longitudinal Observational Follow-up of the PRECEPT Study Cohort
Role: lead
POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's Disease
Role: lead
All 18 trials loaded